Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-01-22
Kewalramani Reshma Files Vertex Pharmaceuticals (VRTX) Form 4 - January 22, 2026
Kewalramani Reshma bought 38.9K VRTX shares in this Form 4 filing, reported to the SEC on 2026-01-22.
- Insider
- Kewalramani Reshma
- Issuer
- Vertex Pharmaceuticals Inc. VRTX · NASDAQ
- Filed
- Period
- 2026-01-22
- Accession
- 0000875320-26-000018
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Kewalramani Reshma | 2026-01-22 | Buy | 27.0K | $0.00 | $0.00 | Direct |
| Kewalramani Reshma | 2026-01-22 | Buy | 11.9K | $0.00 | $0.00 | Direct |
| Net change | +38.9K | $0.00 | ||||
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Track VRTX insider activity
Get alerted when Vertex Pharmaceuticals Inc. executives buy or sell their shares.